Indegene launches new center in London

GSK announces new global headquarters in central London

Company to open new headquarters in 2024

AstraZeneca's Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial

Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo

Dr. Lal PathLabs becomes South Asia's first to launch advanced test for amyloidosis

More than 40 types of Amyloid proteins are discovered till date

GlaxoSmithkline Pharmaceuticals appoints Carson Dalton as Executive VP - Communications and Government Affairs

Carson brings with him over two decades of experience in Communications, Public Affairs, and Sustainability

Sandeep Rao appointed MD and CEO of Solar Active Pharma Sciences

Sarat Kumar has been appointed as CFO of the company and also designated as Key Managerial Personnel with effect from February 21, 2025

Acoramidis receives positive CHMP opinion for treatment of transthyretin amyloid cardiomyopathy

Final decision from the European Commission is anticipated within the coming months

Edwards’ SAPIEN 3 Ultra RESILIA Valve demonstrates positive outcome

Pfizer appoints Chris Boshoff as Chief Scientific Officer and President, Research & Development

Roger Dansey to become Interim Chief Oncology Officer and Johanna Bendell to join Pfizer as Oncology Chief Development Officer

Keytruda plus chemotherapy before surgery reduced risk of death by more than 1/3versus neoadjuvant chemotherapy in high-risk early stage TNBC

KEYTRUDA is the first and only immunotherapy-based regimen to show a statistically significant and clinically meaningful improvement in overall survival